JNJ vs OPK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
OPK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.97 and low debt, these are offset by a -19.2% decline in year-over-year revenue and deeply negative profit margins. The stock is trading below its book value (P/B 0.71), but the persistent long-term price decay (-72.8% over 5 years) suggests a value trap rather than a bargain. Despite optimistic analyst price targets, the deterministic data points to a company in structural decline.
Compare Another Pair
Related Comparisons
JNJ vs OPK: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and OPKO Health, Inc. (OPK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.